Actively Recruiting
Using QPOP to Predict Treatment for Sarcomas and Melanomas
Led by National Cancer Centre, Singapore · Updated on 2025-07-01
100
Participants Needed
1
Research Sites
433 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo. Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.
CONDITIONS
Official Title
Using QPOP to Predict Treatment for Sarcomas and Melanomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of sarcoma or melanoma
- At least 1 tumour lesion amenable to fresh biopsy or resection
- Signed informed consent from patient or legal representative
- Able to comply with study-related procedures
You will not qualify if you...
- There are no specific exclusion criteria if patients meet the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Centre Singapore
Singapore, Singapore, 169610
Actively Recruiting
Research Team
V
Valerie Shiwen Yang, BSc, MB BChir, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here